Cardiovascular mortality (mostly ventricular arrhythmia) reported in (27%) that almost associated with conduction abnormalities (80%) in patients with the combination of either of anti-PD-1/PDL-1 an anti-CLTA-4 and severity of myocarditis was observed in 57% more than those with anti-PD-1/PDL-2 monotherapy [20], [58], [61]. Here, PDCD1 is linked to myocarditis.